MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
16.14
-0.27
-1.65%
After Hours: 16.00 -0.14 -0.87% 19:38 11/10 EST
OPEN
16.17
PREV CLOSE
16.41
HIGH
16.35
LOW
15.46
VOLUME
5.46M
TURNOVER
--
52 WEEK HIGH
39.89
52 WEEK LOW
12.73
MARKET CAP
1.65B
P/E (TTM)
-3.1128
1D
5D
1M
3M
1Y
5Y
1D
Ultragenyx Pharmaceutical (RARE) Could Be 38% Undervalued After UK UX111 Filing Progress
Simply Wall St · 2h ago
Weekly Report: what happened at RARE last week (1102-1106)?
Weekly Report · 1d ago
Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split
NASDAQ · 4d ago
Where Does Ultragenyx Pharmaceutical (RARE) Value Sit After Cost Cuts?
Simply Wall St · 5d ago
Ultragenyx Pharma Is Maintained at Buy by Citigroup
Dow Jones · 5d ago
Ultragenyx Pharma Price Target Cut to $22.00/Share From $32.00 by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $22
Benzinga · 5d ago
Ultragenyx Pharma Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.